OTCMKTS:VYNT Vyant Bio (VYNT) Stock Forecast, Price & News $0.16 +0.01 (+6.67%) (As of 09/21/2023 ET) Add Compare Share Share Today's Range$0.16▼$0.1750-Day Range$0.15▼$0.2852-Week Range$0.14▼$3.15Volume15,701 shsAverage Volume214,562 shsMarket Capitalization$1.01 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort Interest Vyant Bio MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside3,025.0% Upside$5.00 Price TargetShort InterestHealthy0.87% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.01 out of 5 stars 3.3 Analyst's Opinion Consensus RatingVyant Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.00, Vyant Bio has a forecasted upside of 3,025.0% from its current price of $0.16.Amount of Analyst CoverageVyant Bio has received no research coverage in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted0.87% of the outstanding shares of Vyant Bio have been sold short.Short Interest Ratio / Days to CoverVyant Bio has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vyant Bio has recently decreased by 4.02%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldVyant Bio does not currently pay a dividend.Dividend GrowthVyant Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VYNT. Previous Next 3.1 News and Social Media Coverage News SentimentVyant Bio has a news sentiment score of 1.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Vyant Bio this week, compared to 1 article on an average week.MarketBeat Follows1 people have added Vyant Bio to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vyant Bio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.56% of the stock of Vyant Bio is held by insiders. Previous Next 0.6 Earnings and Valuation Price to Book Value per Share RatioVyant Bio has a P/B Ratio of 0.09. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Vyant Bio (OTCMKTS:VYNT) StockVyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). The company is based in Cherry Hill, New Jersey.Read More VYNT Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VYNT Stock News HeadlinesSeptember 20, 2023 | finance.yahoo.comVyant Bio Announces Adjournment of Special Meeting of StockholdersAugust 21, 2023 | yahoo.comMedicare patients took unnecessary genetic cancer tests in man’s $463M scheme, feds saySeptember 21, 2023 | Stansberry Research (Ad)Are "The Magnificent Seven" the Next Sears?The former retail giant’s sales once accounted for 1% of the U.S. economy. Now it’s nearly extinct. Will the same happen to big tech? Learn more here.August 21, 2023 | washingtonpost.com‘Asian glow’ from alcohol isn’t just a discomfort. It’s a severe warning.August 18, 2023 | msn.comGene that vastly increases chance of breast cancer found by scientistsAugust 17, 2023 | msn.comThe dangerous gene that vastly increases your chance of breast cancerAugust 9, 2023 | msn.comAI Can Find Cancer’s Origin: StudyJuly 18, 2023 | benzinga.comGenprex – FDA Grants Fast Track Approval For Promising New Cancer Gene TherapySeptember 21, 2023 | Stansberry Research (Ad)Are "The Magnificent Seven" the Next Sears?The former retail giant’s sales once accounted for 1% of the U.S. economy. Now it’s nearly extinct. Will the same happen to big tech? Learn more here.July 17, 2023 | bizjournals.comVyant Bio enters into deal to sells its microBrain assets for $2.25MJuly 17, 2023 | finance.yahoo.comAxoSim Enters Into a Definitive Agreement to Acquire Vyant Bio's StemoniX AssetsJuly 6, 2023 | msn.comGene editing helped crack a 100-year-old mystery about cancerJuly 3, 2023 | msn.comCertain genetic mutations linked to treatment-resistant breast cancer, new study discoversJuly 3, 2023 | msn.comTesting begins for Orkney cancer gene linkJune 29, 2023 | usatoday.comAre you truly at risk for prostate cancer? Adding genetics may give more accurate PSA testsJune 7, 2023 | msn.comKHCC presents Cancer Genetics study in leading conference in USJune 6, 2023 | msn.comDNA sequencing can lead to longer, better lives for cancer patients. But why do so few get it?June 2, 2023 | msn.comEndometrial Cancer Warning Signs: What to Look Out ForMay 25, 2023 | msn.comUCLA researchers say genetic mutation could be key to treating fatal brain tumorsMay 18, 2023 | msn.comJunk genes may hold keys to cancer cure, CWRU researchers findMay 16, 2023 | technews.tmcnet.comNew Study Shows CancerIQ Plus Point-of-Care Genetic Testing Improves Access to Precision PreventionMay 12, 2023 | proactiveinvestors.comVyant Bio to pursue listing on OTC Pink Open MarketMay 12, 2023 | finance.yahoo.comVyant Bio Announces Last Day of Trading on Nasdaq and Filing of Form 15 for Voluntary Nasdaq Delisting and SEC DeregistrationMay 12, 2023 | marketwatch.com8-K: Vyant Bio, Inc.May 8, 2023 | washingtonpost.comAsk a Doctor: Which cancers can be detected through genetic testing?May 8, 2023 | markets.businessinsider.comGenome Insight Launches in the U.S. with Innovative Whole Genome Sequencing Approach that Offers Unprecedented, Actionable Insights in Cancer CareMay 4, 2023 | finance.yahoo.comVyant Bio Announces Filing of Form 25 for Voluntary Nasdaq Delisting and SEC DeregistrationSee More Headlines Receive VYNT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vyant Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address VYNT Company Calendar Last Earnings11/11/2021Today9/21/2023Next Earnings (Estimated)11/13/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:VYNT CUSIPN/A CIK1349929 Webstemonix.com Phone(201) 479-1357Fax201-528-9201Employees4Year FoundedN/APrice Target and Rating Average Stock Price Forecast$5.00 High Stock Price Forecast$5.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+3,126.0%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-22,690,000.00 Net Margins-3,474.81% Pretax Margin-3,281.86% Return on Equity-151.82% Return on Assets-97.14% Debt Debt-to-Equity Ratio0.04 Current Ratio2.86 Quick Ratio2.86 Sales & Book Value Annual Sales$670,000.00 Price / Sales1.46 Cash FlowN/A Price / Cash FlowN/A Book Value$1.69 per share Price / Book0.09Miscellaneous Outstanding Shares6,330,000Free Float5,724,000Market Cap$981,086.70 OptionableNot Optionable Beta1.79 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Andrew D.C. LaFrence CPA (Age 60)CPA, Pres, CEO & CFO Comp: $407.4kMr. Yung-Ping Yeh M.B.A. (Age 47)M.S., P.M.P., Co-Founder & Director Comp: $22.5kKey CompetitorsZicixOTCMKTS:ZICXOpGenNASDAQ:OPGNAclarionNASDAQ:ACONBioceptNASDAQ:BIOCOncology PharmaOTCMKTS:ONPHView All Competitors VYNT Stock - Frequently Asked Questions Should I buy or sell Vyant Bio stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vyant Bio in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" VYNT shares. View VYNT analyst ratings or view top-rated stocks. What is Vyant Bio's stock price forecast for 2023? 2 brokers have issued 1 year target prices for Vyant Bio's shares. Their VYNT share price forecasts range from $5.00 to $5.00. On average, they anticipate the company's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 3,126.0% from the stock's current price. View analysts price targets for VYNT or view top-rated stocks among Wall Street analysts. How have VYNT shares performed in 2023? Vyant Bio's stock was trading at $0.7025 on January 1st, 2023. Since then, VYNT shares have decreased by 77.9% and is now trading at $0.1550. View the best growth stocks for 2023 here. When is Vyant Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023. View our VYNT earnings forecast. How were Vyant Bio's earnings last quarter? Vyant Bio, Inc. (OTCMKTS:VYNT) posted its quarterly earnings results on Thursday, November, 11th. The company reported ($0.75) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.75). The company earned $1.51 million during the quarter, compared to analysts' expectations of $2.19 million. Vyant Bio had a negative trailing twelve-month return on equity of 151.82% and a negative net margin of 3,474.81%. During the same quarter in the prior year, the firm earned ($2.90) earnings per share. When did Vyant Bio's stock split? Vyant Bio shares reverse split on Wednesday, November 2nd 2022. The 1-5 reverse split was announced on Wednesday, November 2nd 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 2nd 2022. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. What is Vyant Bio's stock symbol? Vyant Bio trades on the OTCMKTS under the ticker symbol "VYNT." How do I buy shares of Vyant Bio? Shares of VYNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Vyant Bio's stock price today? One share of VYNT stock can currently be purchased for approximately $0.15. How much money does Vyant Bio make? Vyant Bio (OTCMKTS:VYNT) has a market capitalization of $981,086.70 and generates $670,000.00 in revenue each year. How can I contact Vyant Bio? Vyant Bio's mailing address is 2370 State Route 70 Suite 310, Cherry Hill NJ, 08002. The official website for the company is stemonix.com. The company can be reached via phone at (201) 479-1357, via email at jzimmons@zimmonsic.com, or via fax at 201-528-9201. This page (OTCMKTS:VYNT) was last updated on 9/21/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vyant Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.